ESG Report 2024

1 01 Performance Highl ights in 2024 1 . 1 Annual Performance Normalising Healthiness -- S afe guarding Life and Health Pursuing Perfection -- Building Quality Brands Source Tracing -- Responsible Supply Chain Management People - Oriented -- Establishing a Solid Foundation for Development Craftsmanship Legacy -- Safeguarding a Green Future The energy consumption per RMB10,000 of industrial output value decreased by 4.9% Recycling rate of reclaimed water 100% The daily water consumption decreased by 10.4% RMB million Annual R&D investment 986 31 Products Included in the National Essential Drugs List 67 Products Included in the National Medical Insurance List 24 Products Passed Consistency Evaluation Effective Governance -- Excellent Operational Management 33 Training sessions on compliance and business ethics were organised during the Year 0 Involved in any data leakage cases 121 Patents for inventions, utility models and designs 0 Incidents of adverse reactions due to defective quality of drug 100% Response rate to user complaints 100% of suppliers receive integrity training provided by the Group 100% Audit qualification rate of major collaborative suppliers 492,686 T otal training hours for employees 37.1% Female management ratio Employee Share Incentive Scheme grants a total of 3,606,180 Shares Collaborate Together -- Building a Better Community RMB Cumulative disbursement of federal medical education scholarships in the Year 250 000 , 26 "Filial Piety Swallows" Charity Activities Conducted in the Year 91,600 ml Total Amount of Blood Donation by Employees in the Year Environmental, Social and Governance Report 2024 The United Laboratories International Holdings Limited ESG Rating Performance MSCI ESG Rating A